TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
Four posters on intravenous and intratumoral cancer treatment presented at SITC
Helsinki, Finland – 6 November 2023: TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference (SITC – San Diego, 1-5 November).
